Efficacy of preceding administration of Entecavir with PEG-IFN-alfa2a for patients with chronic hepatitis B, positive with HBe antigen in young aged populations
Not Applicable
Recruiting
- Conditions
- Chronic hepatitis B
- Registration Number
- JPRN-UMIN000020124
- Lead Sponsor
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 26
Inclusion Criteria
Not provided
Exclusion Criteria
1. HCV antibody positive 2. Liver cirrhosis 3. Pregnancy or lactation period 4. Entecavir or interferon therapy before the study 5. Treated with shou-saikotou (Kampo medicine) 6. Past history of interstitial pneumoniae 7. Past history of autoimmune hepatitis 8. Allergy with vaccination 9. Severe mentally disordered, severe psychotic disease 10. Others
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The ratio of HBV-DNA titer, below 4 log copies/mL after 48 weeks of preceding administration of Entecavir with PEG-IFN-alfa2a
- Secondary Outcome Measures
Name Time Method